Physician's Weekly

JUNE 15, 2025

The following is a summary of “Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment—real world comparative effectiveness from German claims data,” published in the June 2025 issue of BMC Gastroenterology by Dignass et al.

Utilities 52

Utilities Healthcare Individual Patients 52

PEMBlog

MARCH 27, 2024

She did her MD/PhD at Columbia University, where she investigated the diagnostic utility of exome sequencing for kidney disease. Meaning that an individual must inherit two copies of the mutation, so one from each of his or her parents, to be affected. You can contact her via email at egroopman@childrensnational.org. Pediatr Rev.

Consulting 59

Consulting Individual Families Family 59

GeriPal

APRIL 10, 2025

It was really at the level of the ED across 33 EDs in random order, and then tried to see if we could make a difference in healthcare utilization, primarily the primary outcome was admission to the hospital, acute care admission. Eric 26:01 Curtis’s, he had a 2014 JAMA article on simulation. Basically vital talk. No difference.

Patient-Centered 77

Patient-Centered IT Hospital Patients 77

GeriPal

AUGUST 25, 2022

Eric: Whenever I hear about for-profit, non-for-profit, the differences between them, mostly everybody turns to, I think, your 2014 paper looking at the differences between for-profit and non-for-profit. Melissa: The other scenario that exists is just disenrollment because an individual is hospitalized.

Family 106

Family Families IT Patients 106

GeriPal

APRIL 6, 2023

Lexy: Yeah, so I can say that I became about, in 2014, I had the opportunity to lead a center at our health system called the Evans Center that focuses on religion, spirituality, and health. We randomized individual patients either to the SKY framework or to usual care. I don’t see a lot of those out there. Lexy: Yeah.

IT 99

IT Patient-Centered Families Family 99

FDA Law Blog

SEPTEMBER 6, 2021

Briefly (more detail is available here ), GSK sued Teva back in 2014 alleging that Teva induced infringement of a method-of-use patent when Teva marketed a skinny-labeled generic version of GSK’s Coreg (carvedilol) as AB-rated. Especially now with the utility of the use code minimized. Teva decision changed everything.

IT 52

IT Provider ER Insurance 52